International experts show growing interest in means of monitoring cough, the vital, but little used, bio-marker for disease management and identification.

​In late May, Mark Ironmonger, clinical lead for Quvium, attended the
Edwin L. Kendig Jr Pediatric Pulmonary Symposium at the Children’s
Hospital of Richmond at VCU. in Richmond Virginia as a guest of Prof
Bruce Rubin. Professor Rubin holds chairs in Pediatrics and
Biomedical engineering and is highly regarded worldwide for his
innovative work in the field of pediatric pulmonology (or childhood
respiratory disease, depending on from which side of the pond you
originate from). We are fortunate to have him appointed to our
advisory council. There were excellent presentations on many
aspects of respiratory disease from key opinion leads across most
continents.
There was a great deal of interest in our means of monitoring cough,
especially as there is little in the way of technology to objectively
assess this vital, but little used, biomarker for disease management
and identification. There is a reliance on subjective questionnaires
and bulky, laboratory-based equipment to gather such data.
Subsequently, Mark was able to engage with professors from South
Africa, Australia, Israel and the US who are interested in exploring
with us the use of our monitor for such conditions as the recognition
and treatment of infections, such as TB and whooping cough, and
naturally, the anticipation of exacerbations of asthma in children at
risk, and pulmonary disease in cystic fibrosis. These professors are,
of course, in addition to the leading academics from London,
including Great Ormond Street, Kings College and Imperial College,
and from Hull, Leeds, Southhampton and Swansea with whom we
are already working.